Table 3. A Stepwise comparison of genotypic distributions of PTX3 SNPs in case group and control group†.
| SNP genotype | Control group (n=122), n (%) | Case group (n=45) | Case group II (n=30)‡ | Case group III (n=23) § | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | OR (95% CI) | P | n (%) | OR (95% CI) | P | n (%) | OR (95% CI) | P | ||||
| rs2305619 | ||||||||||||
| AA | 22 (18.03) | 9 (20.00) | 1.13 (0.46–2.63) | 0.772 | 7 (23.33) | 1.38 (0.50–3.51) | 0.509 | 7 (30.43) | 1.99 (0.70–5.28) | 0.178 | ||
| AG | 48 (39.34) | 22 (48.89) | 1.47 (0.74–2.94) | 0.269 | 13 (43.33) | 1.18 (0.52–2.64) | 0.69 | 10 (43.47) | 1.19 (0.47–2.91) | 0.711 | ||
| GG | 52 (42.62) | 14 (31.11) | 0.61 (0.29–1.24) | 0.179 | 10 (30.00) | 0.67 (0.28–1.53) | 0.355 | 6 (26.09) | 0.48 (0.16–1.23) | 0.144 | ||
| AG + AA | 70 (57.38) | 31 (68.89) | 1.64 (0.81–3.48) | 0.179 | 20 (60.00) | 1.49 (0.65–3.56) | 0.355 | 17 (73.91) | 2.10 (0.81–6.17) | 0.144 | ||
| GG + AG | 100 (81.97) | 36 (80.00) | 0.88 (0.38–2.17) | 0.772 | 23 (76.67) | 0.72 (0.28–2.01) | 0.509 | 16 (69.66) | 0.50 (0.19–1.44) | 0.178 | ||
| rs3816527 | ||||||||||||
| AA | 72 (59.02) | 20 (44.44) | 0.56 (0.28–1.10) | 0.095 | 11 (36.67) | 0.40 (0.17–0.90) | 0.031* | 8 (34.78) | 0.37 (0.14–0.92) | 0.037* | ||
| AC | 46 (37.70) | 21 (46.67) | 1.45 (0.72–2.89) | 0.221 | 15 (50.00) | 1.56 (0.74–3.72) | 0.221 | 11 (47.83) | 1.51 (0.61–3.73) | 0.364 | ||
| CC | 4 (3.28) | 4 (8.89) | 2.88 (0.65–12.67) | 0.148 | 4 (13.33) | 4.54 (1.01–20.35) | 0.041* | 4 (17.39) | 6.21 (1.37–28.36) | 0.015* | ||
| AC + AA | 118 (96.72) | 41 (91.11) | 0.35 (0.07–1.53) | 0.148 | 26 (86.67) | 0.22 (0.05–0.99) | 0.041* | 19 (82.61) | 0.16 (0.04–0.73) | 0.015* | ||
| AC + CC | 50 (40.98) | 25 (55.56) | 1.80 (0.91–3.62) | 0.095 | 19 (63.33) | 2.49 (1.10–5.84) | 0.031* | 15 (65.22) | 2.70 (1.09–7.16) | 0.037* | ||
| rs1840680 | ||||||||||||
| AA | 19 (15.57) | 5 (11.11) | 0.68 (0.21–1.82) | 0.468 | 4 (13.33) | 0.83 (0.23–2.45) | 0.759 | 4 (17.39) | 1.14 (0.31–3.46) | 0.83 | ||
| AG | 48 (39.34) | 15 (33.33) | 0.77 (0.37–1.56) | 0.478 | 7 (23.33) | 0.47 (0.17–1.13) | 0.107 | 4 (17.39) | 0.32 (0.09–0.91) | 0.052 | ||
| GG | 55 (45.08) | 25 (55.56) | 1.52 (0.77–3.05) | 0.231 | 19 (63.33) | 2.10 (0.94–4.93) | 0.077 | 15 (65.22) | 2.28 (0.92–6.05) | 0.08 | ||
| AG + AA | 67 (54.91) | 20 (44.44) | 0.66 (0.33–1.30) | 0.231 | 11 (36.67) | 0.48 (0.20–1.07) | 0.077 | 8 (34.78) | 0.48 (0.16–1.08) | 0.08 | ||
| GG + AG | 103 (84.43) | 40 (88.89) | 1.48 (0.55–4.69) | 0.468 | 26 (86.67) | 1.20 (0.41–4.40) | 0.759 | 19 (82.61) | 0.88 (0.29–3.27) | 0.83 | ||
†, a stepwise comparison strategy was used to analyze the genotypic distributions of SNPs in the PTX3 region taking into account different pathogeneses of pulmonary mycosis; ‡, in this comparison, 15 patients with ABPA, an allergy endotype, were excluded from the case group. The remaining patients were defined as case group II, which consisted of 10 IPA cases, 18 PC cases, 1 talaromycosis case, and 1 candidiasis case; §, in this comparison, 7 “probable” patients (6 IPA cases and 1 candidiasis case) were excluded from case group II. The remaining patients were defined as case group III, which consisted of 4 IPA cases, 18 PC cases, and 1 talaromycosis case. *, a P value <0.05 indicated a statistically significant difference. ABPA, allergic bronchopulmonary aspergillosis; CI, confidence interval; OR, odds ratio; PC, pulmonary cryptococcosis; PTX3, pentraxin 3; SNP, single nucleotide polymorphism.